Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Survival rates for incurable larynx cancer investigated for first time

2.

findings from the measurement of disability weights in China with an emphasis on the impact of disease burden.

3.

Knowing about and avoiding bladder cancer.

4.

The risk of ovarian cancer is not increased by salpingectomy, according to JAMA.

5.

Aspirin Fails to Boost Survival in Colorectal Cancer Trial


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot